Aragen Life Sciences IPO: Rs 800 Crore Plan Filed with SEBI
By ThePip Desk
Aragen Life Sciences files for an Rs 800 crore IPO with SEBI, including an offer for sale. Funds to be used for debt repayment and capital expenditure.
Aragen Life Sciences Ltd. has filed draft papers with Sebi for an initial public offering (IPO) targeting Rs 800 crore. The offering combines a fresh issue and an offer for sale of 2.73 crore equity shares from existing holders. Goldman Sachs Capital Holdings is among the selling shareholders.
Key IPO Figures
- IPO Target: Rs 800 crore
- Offer for Sale: 2.73 crore equity shares
- Customers (FY26): 591 global clients
- Employees (March 31, 2026): 4,362
Funds from the fresh issue are earmarked for debt repayment. Capital expenditure is also planned for new equipment at Hyderabad facilities and Aragen Biologics Pvt Ltd’s Bengaluru facility. A portion will cover general corporate purposes.
Company Profile
Founded in 2000, Aragen Life Sciences operates as an integrated contract research, development, and manufacturing organisation (CRDMO). It supports global innovator companies and emerging firms in the life sciences sector.
The company provides services spanning contract discovery, pre-clinical research, and contract development and manufacturing for small molecules and biologics. In fiscal year 2026, Aragen served 591 global customers across key markets.
These markets include the US, Europe, Japan, India, and other Asia-Pacific regions. Its diverse client base consists of major pharmaceutical companies, mid-sized pharma and biotech firms, and players in animal health, agrochemicals, and specialty chemicals.
The book-running lead managers for the issue are Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities Pvt Ltd, and JM Financial.